Life science instrument market will witness explosive growth
In the early 1980s, it was predicted that "the 21st century will be the century of biology." This prophecy has now become a reality. Half of the world's top ten technological breakthroughs in the 2014 Science Weekly are from the life sciences. In 2014, scientists made numerous breakthroughs in aging research, biological evolution, genetic analysis of genetic diseases, stem cells, brain and nerve cell research, helping people to reveal secrets about human growth, development, aging, illness and death. Ultimately, it will help people overcome major diseases such as AIDS, cancer and Ebola.
In China, the bio-industry, as one of the seven strategic emerging industries listed in the “Decision of the State Council on Accelerating the Cultivation and Development of Strategic Emerging Industriesâ€, has become the focus of policy and funding in recent years. In 2014, in the 863 and 973 programs, the biological field remained the most invested area. In the "Bio-Industry Development Plan", the development target of the bio-industry output value maintained at an average annual growth rate of more than 20% in the past three years has been formulated, which indicates that China's bio-industry has entered a period of rapid development. Important fields of bio-industry, bio-agriculture and other bio-industries will inevitably increase investment in related production and R&D.
The development of the bio-industry will inevitably bring huge market opportunities to life science instruments, an important tool in the life sciences. According to related research reports, in 2014, the global life science instrument market sales exceeded $40 billion and grew at a rate of 6%. For the Chinese market, despite the slowdown in economic growth, the country's support and the huge procurement demand brought about by the booming bio-industry make the Chinese market the most powerful driving force for life science instruments.
The molecular diagnostics market is still one of the hot spots in the development of life sciences. In 2014, the global molecular diagnostics market grew at a rate of more than 10%, while the Chinese molecular diagnostics market grew by more than 20%. In another life science hotspot, biological breeding with GM technology as the core is the leader of bio-agriculture development in China. The rapid development of these hotspots has driven the procurement of related research tools – gene sequencers , PCR instruments and other molecular cell biology instruments.
Foreign media predicts that in the past three years, with the development of molecular diagnostics, biomedicine and other fields, fluorescence quantitative PCR, second-generation sequencing (NGS) / third-generation sequencing (3GS), chips, PCR, CE sequencing, digital Genomics related instruments such as PCR; proteomics instruments such as protein separation and analysis equipment, ELISA, blotting and protein chips; cell biology instruments such as flow cytometry and microscopy will generate a large market scale.
In response to the booming life sciences industry, major instrument companies have stepped up their efforts in the transformation of life sciences. Agilent is focusing more on biomedical technology through splitting in order to achieve greater growth in the life sciences and diagnostics business; Merck and Danaher accelerate their expansion into life sciences through acquisitions; Brooke sells ICP-MS business Its focus shifts to one of the important strategies in the life sciences. It is not difficult to see that the field of life science has become a must for major instrument companies.
Genetic Sequencer: Rapid Development in Policy Change
Gene sequencing is a revolutionary technology that brings a wide range of applications. In recent years, with the advancement of gene sequencing technology, the gene sequencing industry has entered a period of rapid development.
Gene sequencing technology is an important technical tool in life science research, and is an indispensable research tool for molecular diagnosis and biomedicine. In 1977, Sanger's end-stop sequencing method (first-generation sequencing technology) combined with capillary electrophoresis, which has become a mainstream method for gene sequencing, has been widely used in scientific research and clinical work because of its simple and rapid characteristics. With the booming of personalized medicine , gene sequencing technology has played an increasingly important role in clinical, forensic, CDC and other applications.
The Implementation Plan for the Comprehensive Promotion of Blood Station Nucleic Acid Detection (2013-2015) issued by the National Health and Family Planning Commission (STI). It is required to build a network of blood station nucleic acid testing laboratories with reasonable overall layout, efficient resource allocation and perfect detection function. By 2015, blood screening nucleic acid testing will cover the whole country. Promoted the market demand for the 2014 gene sequencer.
On February 9, 2014, the State Food and Drug Administration and the Office of the National Health and Family Planning Commission issued a notice on the official website to urgently stop the use of genetic sequencing related products and technologies in clinical medicine. The root cause of gene sequencing is that the companies engaged in genetic testing are mixed and the market is chaotic. Gene sequencing involves a series of issues such as ethics, privacy and protection of human genetic resources, biosafety, and medical institutions to carry out genetic diagnosis service technology management, price, quality supervision, etc. Regulators must regulate the industry, and it is not a problem with the technology of gene sequencing itself. On the contrary, due to the advantages of gene sequencing in prenatal diagnosis, with the opening of the “two children alone†policy, the number of elderly women is gradually increasing, and the demand for gene sequencing is increasing.
This is exactly the case. On July 2, the State Food and Drug Administration (CFDA) announced that it has approved the BGISEQ-1000 gene sequencer, BGISEQ-100 gene sequencer and fetal chromosome aneuploidy (T21, T18). , T13) detection kit (combined probe anchor connection ligation method), fetal chromosome aneuploidy (T21, T18, T13) detection kit (semiconductor sequencing method) medical device registration. According to the State Food and Drug Administration, this is the second generation of genetic sequencing diagnostic products approved for registration in China for the first time. After the gene sequencing was stopped for more than four months, the second-generation gene sequencing products ushered in the re-opening of the dawn in clinical medical applications. On November 5th, Daan Gene Co., Ltd. gene sequencer and Down's non-invasive test kit also obtained CFDA production approval documents.
Recently, the Health Planning Commission evaluated and published the first batch of high-throughput sequencing technology clinical application pilot units, approved the genetic diagnosis major, prenatal screening and diagnosis, preimplantation embryo genetic diagnosis professional gene sequencing clinical Pilot. This means that the gene sequencing and related reporting units can formally apply the project to the medical system, and it can be said to be of great clinical impact.
Plant Support,Plant Spiral Wire,High Quality Twine Wire,Tomato Spiral Stake
JIANGSU SKYPLAN GREENHOUSE TECHNOLOGY CO.,LTD , https://www.skyplantgreenhouse.com